1. Home
  2. GTBP vs ZBAI Comparison

GTBP vs ZBAI Comparison

Compare GTBP & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTBP
  • ZBAI
  • Stock Information
  • Founded
  • GTBP 1965
  • ZBAI 2015
  • Country
  • GTBP United States
  • ZBAI United States
  • Employees
  • GTBP N/A
  • ZBAI N/A
  • Industry
  • GTBP Biotechnology: Pharmaceutical Preparations
  • ZBAI Professional Services
  • Sector
  • GTBP Health Care
  • ZBAI Consumer Discretionary
  • Exchange
  • GTBP Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • GTBP 5.5M
  • ZBAI 6.4M
  • IPO Year
  • GTBP N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • GTBP $1.77
  • ZBAI $0.36
  • Analyst Decision
  • GTBP Strong Buy
  • ZBAI
  • Analyst Count
  • GTBP 1
  • ZBAI 0
  • Target Price
  • GTBP $11.00
  • ZBAI N/A
  • AVG Volume (30 Days)
  • GTBP 74.2K
  • ZBAI 8.3M
  • Earning Date
  • GTBP 08-13-2025
  • ZBAI 06-06-2025
  • Dividend Yield
  • GTBP N/A
  • ZBAI N/A
  • EPS Growth
  • GTBP N/A
  • ZBAI N/A
  • EPS
  • GTBP N/A
  • ZBAI N/A
  • Revenue
  • GTBP N/A
  • ZBAI $720,000.00
  • Revenue This Year
  • GTBP N/A
  • ZBAI N/A
  • Revenue Next Year
  • GTBP N/A
  • ZBAI N/A
  • P/E Ratio
  • GTBP N/A
  • ZBAI N/A
  • Revenue Growth
  • GTBP N/A
  • ZBAI 44.00
  • 52 Week Low
  • GTBP $1.72
  • ZBAI $0.27
  • 52 Week High
  • GTBP $4.10
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • GTBP 31.45
  • ZBAI N/A
  • Support Level
  • GTBP $2.01
  • ZBAI N/A
  • Resistance Level
  • GTBP $2.11
  • ZBAI N/A
  • Average True Range (ATR)
  • GTBP 0.14
  • ZBAI 0.00
  • MACD
  • GTBP -0.01
  • ZBAI 0.00
  • Stochastic Oscillator
  • GTBP 8.77
  • ZBAI 0.00

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: